Showing 4091-4100 of 5362 results for "".
- Henry Ford Innovations, Google Cloud, and Miracle Software Systems to Fund Innovations Focused on Health Inequitieshttps://practicaldermatology.com/news/henry-ford-innovations-google-cloud-and-miracle-software-systems-to-fund-innovations-focused-on-health-inequities/2460782/Entrepreneurs with ideas for reducing health inequities through the use of digital technology could garner $75,000 in cash and in-kind support toward developing their digital solution at Henry Ford Health System.
- Daily Avena Sativa Skincare Regimen Improves Itch and Dry Skin in Adults Undergoing Systemic Cancer Treatmentshttps://practicaldermatology.com/news/daily-avena-sativa-skincare-regimen-improves-itch-and-dry-skin-in-adults-undergoing-systemic-cancer-treatments-1/2460780/Daily Avena Sativa (Oat) skincare regimen provides a significant improvement in xerosis and pruritus for adult patients undergoing systemic oncology treatments,according to research presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021. "The u
- Sirnaomics Starts Phase 2b Study of STP705 for SCChttps://practicaldermatology.com/news/sirnaomics-inc-starts-phase-2b-study-of-stp705-for-scc/2460778/Sirnaomics, Inc. is initiating a Phase 2b study of STP705 for the treatment of squamous cell skin cancer. STP705 is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery
- New York City's Mount Sinai Launches Melanoma and Skin Cancer Centerhttps://practicaldermatology.com/news/new-york-citys-mount-sinai-launches-melanoma-and-skin-cancer-center/2460777/Mount Sinai received a second $10 million gift from the Waldman Family to open the Kimberly and Eric J. Waldman Melanoma and Skin Cancer Center at Mount Sinai. Housed within the Kimberly and Eric J. Waldman Department of Dermatology at the May
- Additional Data from Incyte's Phase 3 Studies of Topical Ruxolitinibhttps://practicaldermatology.com/news/additional-data-from-incytes-phase-3-studies-of-topical-ruxolitinib/2460774/Findings from three pooled analyses of Incyte’s randomized, double-blind, vehicle-controlled phase 3 studies evaluating ruxolitinib cream add to previously published data for the investigational topical JAK1/JAK2 inhibitor for atopic dermatitis. Presented at the AAD VMX 2021, new
- Skin Bleaching for a Lighter Complexion Carries Serious Riskshttps://practicaldermatology.com/news/skin-bleaching-for-a-lighter-complexion-carries-serious-risks/2460769/Despite the potential dangers of skin bleaching products, the global market for skin lighteners last year was estimated at $8.6 billion and is projected to reach $12.3 billion by 2027. “The cultural beliefs that promote the practice of skin bleaching date back centuries
- Visible Light from the Sun Causes Pigmentary Skin Changeshttps://practicaldermatology.com/news/visible-light-from-the-sun-causes-pigmentary-skin-changes/2460768/Visible light from the sun plays a significant role in causing pigmentary skin changes, particularly in people with skin of color, according to information presented at AAD VMX 2021. “We know from decades of research that unprotected exposure to ultraviolet light from the sun can
- Roflumilast Foam and Cream Show Promise in Multiple Skin Diseaseshttps://practicaldermatology.com/news/roflumilast-foam-and-cream-show-promise-in-multiple-skin-diseases/2460767/Roflumilast foam significantly improved both scalp and body psoriasis, with improvement as early as two weeks after treatment initiation, data presented at the 2021 AAD VMX show. Additionally, data presented in posters at the AAD VMX show that roflumilast foam is a safe, well-tolerated, and effec
- Leo Pharma’s Tralokinumab Produces Sustained Improvement in ADhttps://practicaldermatology.com/news/leo-pharmas-tralokinumab-produces-sustained-improvement-in-ad/2460766/Leo Pharma’s tralokinumab 300 mg every other week plus optional topical corticosteroids (TCS) showed long-term improvements in itch, sleep, and in atopic dermatitis signs and symptoms, according to an interim analysis at 56 weeks in the ECZTEND trial that was presented at the AAD
- Promising Phase 3 Data for Oral Deucravacitinib from Bristol Myers Squibb in Psoriasishttps://practicaldermatology.com/news/promising-phase-3-data-for-oral-deucravacitinib-from-bristol-myers-squibb-in-psoriasis/2460765/In two pivotal Phase 3 trials evaluating deucravacitinib 6mg once daily for the treatment of patients with moderate to severe plaque psoriasis, significantly more patients met both co-primary endpoints—Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global